Jason Kelly is the CEO of Ginkgo Bioworks, a leading biotechnology company focused on programming cells to produce useful products. He has a background in biological engineering and chemical engineering from MIT, giving him a solid foundation in the field....
Jason Kelly is the CEO of Ginkgo Bioworks, a leading biotechnology company focused on programming cells to produce useful products. He has a background in biological engineering and chemical engineering from MIT, giving him a solid foundation in the field. Jason co-founded Ginkgo in 2008, and under his leadership, the company made significant contributions to fighting the COVID-19 pandemic by optimizing vaccine manufacturing and conducting extensive virus testing. In 2022, Ginkgo launched innovative programs to help tackle environmental challenges and improve biosecurity, reflecting a strong commitment to using biotechnology for the greater good. Interestingly, throughout his tenure, Jason has focused on improving Ginkgo's operational efficiencies and expanding its market reach, which has positioned the company as a key player in the bioeconomy. As of 2023, his total compensation was $262,500, reflecting a focus on long-term success rather than immediate financial rewards. Jason is not just a scientist; he's a valuable leader shaping the future of biotech.